Pimera Therapeutics
Pimera Therapeutics, Inc. is a privately held, clinical-stage biotechnology company focused on developing breakthrough therapeutics for cancer and other major unmet medical needs. Pimera’s lead program, PMR-116, is designed to target dysregulated RNA polymerase I (Pol I) transcription in MYC-driven cancers. Pol I transcription of ribosomal RNA genes is tightly regulated downstream of oncogenic pathways, and its dysregulation is a common feature in cancer and other human diseases. Pimera is advancing PMR-116 through dose escalation in a Phase 1a/1b clinical trial.
7-day free trial · no credit card
Verified contacts
1
available on Kipplo
LinkedIn employees
1
1 to 10 range
Open roles
—
no listings
Distinct roles
1
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 1 verified contacts at Pimera Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
1 contacts with verified email or phone · masked until revealed.
Showing 1 of 1 verified contacts
Top roles at Pimera Therapeutics
1 distinct titles indexed · top 1 shown.
- 1co-founder, board of directors member
Sign up to unlock all 1 contacts at Pimera Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 1 verified contacts at Pimera Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.